2cureX AB has initiated the process to get its shares admitted to a new trading venue
2cureX AB (the “Company”) announces that it has initiated the listing process of getting the Company’s shares traded on Spotlight Stock Market.
The process follows Nasdaq Stockholm’s decision to delist the Company’s shares from Nasdaq First North Growth Market, with 31 August 2026 as the final day of trading. The Company adamantly opposes this decision and will continue with its long-term growth plan.
The Company has therefore commenced the listing process with Spotlight Stock Market. Due to the very short notice provided by Nasdaq, there will be a brief period, from 31 August until the shares are re-listed, during which the shares cannot be traded.
The Board’s first objective is to establish an appropriate public trading venue for the Company’s shares and provide continued transparency and accessibility for shareholders.
2cureX AB will provide further information as the process develops and as soon as there is material information to disclose.
“This is highly unfortunate and difficult to understand since we have clearly shown through an oversubscribed directed issue in April that 2cureX is clearly moving forward. We have no time to waste and we will solve this ASAP.” - CEO Nathaniel Hutley
For more information about 2cureX:
Nathaniel Hutley, Interim CEO
E-mail: NH@2curex.com
Telephone: +44 (776) 514 1346
About 2cureX
2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
• IndiTreat® Start (first-line therapy)
• IndiTreat® Extend & Explore (third-line options)
New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.
2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.
This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-08-25 10:30 CEST.